Darrin Crisitello, Nigel Beard, and Marcel Roche join Mission Bio, bringing extensive experience in scaling advanced genomics technologies and markets to over $1 billion in revenue
SOUTH SAN FRANCISCO, Calif. (April 25, 2019) Mission Bio, Inc., the pioneer in high-throughput single-cell DNA analysis and precision genomics, today announced the addition of three key members to its executive team.
Darrin Crisitello joins the Mission Bio team as Chief Commercial Officer with over 19 years of experience in commercial leadership and business development. Previously, Crisitello led the global clinical teams at Color Genomics and Natera, where he was responsible for successfully building the teams to scale during their growth phases. “Mission Bio is revolutionizing how we approach cancer research, drug development and patient care,” remarked Crisitello. “It’s a privilege to join such an intelligent, highly-qualified and driven team. I look forward to getting our platform into even more hands, from researchers to clinicians and drug developers, with the ultimate goal of moving into laboratories as a diagnostic to provide information that can help save patient lives.”
Nigel Beard, Ph.D. joins as SVP of Research and Development (R&D) with over 18 years of experience in strategic technology development and delivery of new product opportunities. He has launched more than 50 products and been an inventor on more than 40 patents, with expertise in next generation sequencing (NGS), microfluidics, AI and machine learning. Beard’s experience from GSK and Life Technologies to start-ups like Feetz creates the foundation to build the next innovations and scale in single-cell genomics. “I’m thrilled to join Mission Bio at a time of rapid growth, especially as we witness this explosion in big data in single cell genomics,” Beard said. “Having devoted my career to genomics and machine learning product development, I believe Mission Bio is the most exciting company to combine these disciplines in pursuit of better patient outcomes.”
Marcel Roche joins as SVP of Finance and Administration with 15 years of experience building finance organizations in leading life science companies like Illumina. Prior to Mission Bio, he served as VP of Finance at Achaogen and at Guardant Health. “It’s been incredible to help scale up the sequencing market at Illumina, and then expand the market into liquid biopsy at Guardant. I see Mission Bio as the next frontier of genomics,” explained Roche.
“Our goal at Mission Bio is to predict and prevent cancer relapse,” explained CEO Charlie Silver. “Adding some of the brightest minds in the industry to our team is a strong testament to the power of our innovation, and we’re honored to welcome them to the team.”
To learn more, visit www.cnmissionbio.wpengine.com.
About Mission Bio
Mission Bio delivers targeted solutions for high impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first single-cell DNA sequencing platform, enabling precise detection of heterogeneity in disease progression and treatment response. Application areas include blood cancers, solid tumors, and genome editing validation. The platform includes an instrument, consumables and software, which plug seamlessly into existing NGS workflows.
The company’s Tapestri Platform was also honored as a Top 10 Innovation of 2018 by The Scientist, as well as utilized by researchers at MD Anderson Cancer Center (MDACC) for the largest single-cell study completed to date. With Mission Bio, researchers have a highly sensitive, targeted, and customizable solution to move precision medicine forward.
VSC for Mission Bio